BNP Paribas Arbitrage SA increased its stake in Alkermes PLC (NASDAQ:ALKS) by 81.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,564 shares of the company’s stock after buying an additional 14,616 shares during the period. BNP Paribas Arbitrage SA’s holdings in Alkermes PLC were worth $1,888,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. FMR LLC increased its stake in shares of Alkermes PLC by 0.4% in the first quarter. FMR LLC now owns 22,882,118 shares of the company’s stock valued at $1,338,604,000 after buying an additional 86,546 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Alkermes PLC by 4.3% in the first quarter. Vanguard Group Inc. now owns 12,096,635 shares of the company’s stock valued at $707,654,000 after buying an additional 497,421 shares during the last quarter. BlackRock Inc. increased its stake in shares of Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock valued at $602,115,000 after buying an additional 10,121,839 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock valued at $459,608,000 after buying an additional 1,480,273 shares during the last quarter. Finally, Woodford Investment Management Ltd increased its stake in shares of Alkermes PLC by 0.3% in the first quarter. Woodford Investment Management Ltd now owns 7,470,528 shares of the company’s stock valued at $437,026,000 after buying an additional 19,400 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Shares of Alkermes PLC (NASDAQ:ALKS) opened at 49.72 on Friday. The stock’s 50 day moving average is $53.48 and its 200-day moving average is $56.81. The company’s market cap is $7.64 billion. Alkermes PLC has a one year low of $41.93 and a one year high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company had revenue of $218.80 million during the quarter, compared to analyst estimates of $216.54 million. During the same period last year, the business earned ($0.01) earnings per share. Alkermes PLC’s revenue was up 12.1% compared to the same quarter last year. Equities research analysts forecast that Alkermes PLC will post ($0.04) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/alkermes-plc-alks-shares-bought-by-bnp-paribas-arbitrage-sa/1537446.html.

Several analysts recently commented on ALKS shares. ValuEngine raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday. Jefferies Group LLC set a $69.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Friday, August 25th. BidaskClub downgraded shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. Finally, Credit Suisse Group set a $70.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $62.89.

In other news, Director Paul J. Mitchell sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total value of $82,365.00. Following the completion of the transaction, the director now directly owns 9,500 shares in the company, valued at $521,645. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Shane Cooke sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $60.33, for a total transaction of $603,300.00. Following the completion of the transaction, the insider now owns 84,708 shares of the company’s stock, valued at $5,110,433.64. The disclosure for this sale can be found here. Insiders sold 13,000 shares of company stock valued at $772,830 over the last 90 days. 5.34% of the stock is owned by company insiders.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.